CD4 and neutropenia: It was, however, agreed to emphasize that neutropenia grade III or IV have been reported in 1.5% of MS patients in the second year after alemtuzumab treatment [15], and that it was plausible that neutropenia in combination with low CD4+ T cell counts induced by alemtuzumab contributed to aspergillus pneumonia and death.